STRO-002 Shows Early Efficacy and Safety in Heavily Pretreated Epithelial Ovarian Cancer

Cancer research · Ovarian cancer

The novel anti‑folate receptor alpha antibody‑drug conjugate STRO‑002 demonstrated encouraging efficacy with a tolerable safety profile in patients with advanced platinum‑resistant or refractory epithelial ovarian cancer.

STRO‑002, an anti‑folate receptor alpha (FOLR1) antibody‑drug conjugate, showed an overall response rate (ORR) of 24 % in 33 evaluable patients with advanced platinum‑resistant or refractory epithelial ovarian cancer in a dose‑escalation/expansion phase I study (NCT03748186). Durability of response was seen in 44 % of patients treated for ≥16 weeks and 12 % treated for ≥1 year, with a disease‑control rate (DCR) of 47 %. The safety profile was tolerable, with most adverse events being grade 1–2. These interim results suggest STRO‑002 may provide a novel therapeutic option for heavily pretreated ovarian cancer patients.

This study demonstrates that STRO‑002 may achieve clinically meaningful responses in platinum‑resistant or refractory epithelial ovarian cancer—a population with limited effective treatments—while maintaining an acceptable safety profile, thereby offering a potential new therapeutic avenue.

Evidence level: Állatkísérletes. Állatmodellben vizsgálták.

Original source

Related signals